Regulation of the Tumor Microenvironment by KSHV

KSHV 对肿瘤微环境的调节

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Kaposi's sarcoma (KS) remains the most common tumor arising in patients with HIV/AIDS, and involvement of the oral cavity represents one of the most common clinical manifestations of this tumor. Kaposi's sarcoma-associated herpesvirus (KSHV) replication and ongoing infection of target cells plays an important role in KS pathogenesis. An amino acid membrane transport protein subunit, xCT, maintains intracellular glutathione stores to enhance the survival of cells producing reactive nitrogen species (RNS), and xCT was recently identified as a fusion-entry receptor for KSHV (Kaleeba and Berger, Science, 2006). A number of intracellular and extracellular triggers regulate xCT expression, including binding of the xCT promoter by transcription regulators and the activation of positive transcription regulators by RNS. We have determined recently that xCT is expressed by multiple cell types within KS lesions and circulating mononuclear cells from HIV-infected patients, with cells from KSHV/HIV co-infected patients exhibiting the highest xCT expression. However, it is unknown whether KSHV itself regulates xCT expression to promote KSHV infection and persistence in the local environment. KSHV infects macrophages within KS lesions, and macrophages are a principal source of RNS. Using a novel macrophage cell culture system, our preliminary data suggest that KSHV microRNA suppress BACH-1, a negative transcription regulator of xCT expression, and that KSHV induces RNS secretion by macrophages. Based on these preliminary data, we hypothesize that KSHV promotes its own persistence in the local environment by upregulating xCT expression through both paracrine and autocrine mechanisms, and that targeting xCT regulatory pathways reduces KSHV infection and persistence in the microenvironment. To address this hypothesis, we propose two independent aims: 1) to determine mechanisms and functional outcomes for xCT regulation by KSHV; and 2) to determine clinical relationships between KSHV infection, xCT expression and RNS production in HIV-infected patients at greatest risk for KS. Through these efforts, we hope to provide the framework for developing novel therapeutic strategies for KS through the targeting of xCT and the reduction of KSHV infection and persistence within the tumor microenvironment.
项目概要/摘要 卡波西肉瘤(KS)仍然是艾滋病毒/艾滋病患者中最常见的肿瘤,并且涉及 口腔的病变是这种肿瘤最常见的临床表现之一。卡波西的 肉瘤相关疱疹病毒(KSHV)的复制和靶细胞的持续感染起着重要作用 在 KS 发病机制中的作用。氨基酸膜转运蛋白亚基 xCT 维持细胞内 谷胱甘肽储存可增强产生活性氮 (RNS) 的细胞的存活率,xCT 是 最近被鉴定为 KSHV 的融合进入受体(Kaleeba 和 Berger,Science,2006)。一些 细胞内和细胞外触发器调节 xCT 表达,包括通过以下方式结合 xCT 启动子 转录调节因子和 RNS 激活正转录调节因子。我们已经确定 最近发现 xCT 由 KS 病变内的多种细胞类型和循环单核细胞表达 来自 HIV 感染患者的细胞,其中来自 KSHV/HIV 共感染患者的细胞表现出最高的 xCT 表达。但尚不清楚KSHV本身是否调节xCT表达来促进KSHV 感染并在当地环境中持续存在。 KSHV 感染 KS 病变内的巨噬细胞,并且 巨噬细胞是 RNS 的主要来源。使用新型巨噬细胞培养系统,我们初步 数据表明 KSHV microRNA 抑制 BACH-1(xCT 表达的负转录调节因子), KSHV 诱导巨噬细胞分泌 RNS。根据这些初步数据,我们 假设 KSHV 通过上调 xCT 来促进其自身在局部环境中的持久性 通过旁分泌和自分泌机制表达,并针对 xCT 调节 途径减少 KSHV 感染和在微环境中的持续存在。为了解决这个问题 假设,我们提出两个独立的目标:1)确定机制和功能结果 xCT 由 KSHV 监管; 2) 确定 KSHV 感染与 xCT 之间的临床关系 KS 风险最大的 HIV 感染患者的表达和 RNS 产生。通过这些努力,我们 希望通过针对 KS 的靶向开发新的治疗策略提供框架 xCT 以及减少 KSHV 感染和肿瘤微环境中的持续存在。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher H Parsons其他文献

Phase I study of pembrolizumab in people with HIV and cancer.
帕博利珠单抗 (pembrolizumab) 在艾滋病毒和癌症患者中的 I 期研究。
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    45.3
  • 作者:
    T. Uldrick;P. Goncalves;Moh. Abdul Hay;A. Claeys;B. Emu;M. Ernstoff;L. Fong;J. C. Kaiser;H. Kohrt;Andreanne M. Lacroix;Steve Y Lee;Lisa M Lundgren;K. Lurain;Christopher H Parsons;Sharavi Peeramsetti;R. Ramaswami;E. Sharon;C. Wang;R. Yarchoan;M. Cheever
  • 通讯作者:
    M. Cheever

Christopher H Parsons的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher H Parsons', 18)}}的其他基金

HIV Clinical Tumor Biorepository (HTCB) Core
HIV 临床肿瘤生物样本库 (HTCB) 核心
  • 批准号:
    10223344
  • 财政年份:
    2017
  • 资助金额:
    $ 12.3万
  • 项目类别:
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
一项评估 ABC294640 在难治性/再发性骨髓瘤患者中的早期临床试验
  • 批准号:
    8790667
  • 财政年份:
    2014
  • 资助金额:
    $ 12.3万
  • 项目类别:
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
一项评估 ABC294640 在难治性/再发性骨髓瘤患者中的早期临床试验
  • 批准号:
    8928574
  • 财政年份:
    2014
  • 资助金额:
    $ 12.3万
  • 项目类别:
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
一项评估 ABC294640 在难治性/再发性骨髓瘤患者中的早期临床试验
  • 批准号:
    9120662
  • 财政年份:
    2014
  • 资助金额:
    $ 12.3万
  • 项目类别:
KSHV REGULATION OF INNATE CYTOKINE RESPONSES AND T CELL ACTIVATION
KSHV 对先天细胞因子反应和 T 细胞激活的调节
  • 批准号:
    8360484
  • 财政年份:
    2011
  • 资助金额:
    $ 12.3万
  • 项目类别:
Regulation of the Tumor Microenvironment by KSHV
KSHV 对肿瘤微环境的调节
  • 批准号:
    8403765
  • 财政年份:
    2010
  • 资助金额:
    $ 12.3万
  • 项目类别:
KSHV REGULATION OF INNATE CYTOKINE RESPONSES AND T CELL ACTIVATION
KSHV 对先天细胞因子反应和 T 细胞激活的调节
  • 批准号:
    8167769
  • 财政年份:
    2010
  • 资助金额:
    $ 12.3万
  • 项目类别:
Lipid Metabolism and KSHV-associated Lymphoma Pathogenesis
脂质代谢和 KSHV 相关淋巴瘤发病机制
  • 批准号:
    7928552
  • 财政年份:
    2010
  • 资助金额:
    $ 12.3万
  • 项目类别:
Regulation of the Tumor Microenvironment by KSHV
KSHV 对肿瘤微环境的调节
  • 批准号:
    8588216
  • 财政年份:
    2010
  • 资助金额:
    $ 12.3万
  • 项目类别:
Regulation of the Tumor Microenvironment by KSHV
KSHV 对肿瘤微环境的调节
  • 批准号:
    7929373
  • 财政年份:
    2010
  • 资助金额:
    $ 12.3万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.3万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了